Public-Private Partnership Roundup
Highlights of public-private partnerships from 1Q15
PPP activity in 1Q15 picked up where it left off at the end of last year, with 54 new partnerships disclosed, and big pharmas or biotechs accounting for 20 of those collaborations. AstraZeneca plc led the way with six deals, including three announced on Jan. 29 involving the use of CRISPR technology in a research capacity. Boehringer Ingelheim GmbH announced three academic collaborations and Johnson & Johnson's Janssen Biotech Inc. subsidiary had two.
Johnson & Johnson doubled down on its interest in developing biology about the microbiome with a new collaboration between its Janssen unit and the Alimentary Pharmabiotic Centre's (APC) Microbiome Institute of Cork. The new partnership was announced in March, only a month after the Janssen Human Microbiome Institute (JHMI) was launched to research links between the microbiome and autoimmune and inflammatory diseases...